trending Market Intelligence /marketintelligence/en/news-insights/trending/n-CbPlTmiheJ9hu1SQ396Q2 content esgSubNav
In This List

Bristol-Myers, Taris to evaluate Opdivo combo in bladder cancer

Blog

Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Blog

Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share

Blog

Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet


Bristol-Myers, Taris to evaluate Opdivo combo in bladder cancer

Bristol-Myers Squibb Co. and Taris BioMedical LLC will collaborate to evaluate Taris' TAR-200, in combination with Bristol-Myers' Opdivo, in patients with bladder cancer.

Under the collaboration, the combination will be evaluated in a phase 1b trial in patients with muscle invasive bladder cancer who are scheduled for radical cystectomy, or the removal of the entire bladder.

Bristol-Myers also made an equity investment in TARIS as part of the collaboration.